Dr Kelvin Ng oversees strategic innovation at the Bioprocessing Technology Institute, one of the 20 research institutes under the Agency for Science, Technology & Research (A*STAR) in Singapore. In this role, he targets biomanufacturing industries ranging from biosimilars, cell/gene therapies, to cultured meat. In another role that serves A*STAR at large, he supports the scientific, business, and regulatory aspects of alternative proteins as future foods, in the execution of Singapore’s S$144-million commitment to address food security through public research.
Kelvin leverages his industry experience in product and process development. At RoosterBio, he established cGMP-compliant workflows to scale up the production of human stem cells, in preparation for FDA filings. He additionally pioneered a new product line and proprietary technologies for the exosome market. A bioengineer by training, Kelvin obtained his PhD at the joint Health Sciences & Technology program between Massachusetts Institute of Technology and Harvard Medical School. Food is always on Kelvin’s mind: he lives to eat and loves to taste ideas.